Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
ARLINGTON, Va., April 12, 2016 -- FBR & Co. (Nasdaq:FBRC) (FBR), a leading investment bank serving the middle market, announced that Chris Meekins recently joined its equity research group and has initiated coverage on healthcare policy. Mr. Meekins is based in the Company’s Arlington, VA headquarters.
“Chris’s addition to our team brings a meaningful and unique policy perspective to our healthcare research that our clients want,” said FBR’s Director of Research and Senior Managing Director, David Hilal. “We have a great tradition of weaving together actionable investment ideas that are at the intersection of government policy and fundamental analysis. For the healthcare industry in particular, this differentiated approach provides our clients with tremendous value.”
Mr. Meekins came to FBR having spent four years as a senior health policy advisor and Chief of Staff for Congressman Andy Harris, M.D. During his tenure there, he helped pass reforms to the National Institutes of Health, increase funding for bio-defense, expand access to organs for transplantation, improve Medicare payments for physicians and increase transparency at the Food and Drug Administration. Before serving on the Hill, he worked in government affairs for the American Society of Anesthesiologists. Mr. Meekins holds a Bachelors of Arts from Gardner-Webb University.
FBR & Co. (Nasdaq:FBRC) provides investment banking, merger and acquisition advisory, institutional brokerage, and research services through its subsidiaries FBR Capital Markets & Co. and MLV & Co. FBR focuses capital and financial expertise on the following industry sectors: consumer; energy & natural resources; financial institutions; healthcare; industrials; insurance; real estate; and technology, media & telecom. FBR is headquartered in the Washington, D.C. metropolitan area with offices throughout the United States. For more information, please visit www.fbr.com.
Contacts Media: Shannon Hawkins at 703.469.1190 or [email protected] Investors: Linda E. Eddy at 703.312.9715 or [email protected]
